An evidence-based web-app helped children with epilepsy to fall asleep on average 16.5 minutes earlier. A new UK-wide ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

A study by Tinder-owner Match Group, “Singles in America”, shows that 26% of people are using AI tools in dating, while the ...

It's hardly a revelation that we're living in an era of distraction and smartphone addiction. Our phones interrupt us, hijack ...

Atacicept is a recombinant fusion protein that binds to and inhibits the activity of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand).

More people are resolving to spend less time on their phones and social media, and research suggests there are health ...

Admission to MIT demands far more than strong marks or test scores. The institute looks for students who can thrive in an ...

As consumer prices continue to fluctuate, thanks to things like inflation and tariffs, Walmart is opting to refresh its ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...

Writing things down isn't so common in the digital age we live in, but science shows there are major advantages to doing so.

From Alexa to ChatGPT, our interactions with AI are reshaping communication norms. Here's why how we talk to machines can affect real human relationships.

FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Desi ...